First quarter 2022 EPS estimates for ResMed Inc. augmented by William Blair (NYSE: RMD)

0

ResMed Inc. (NYSE: RMD) – William Blair raised his estimate of first quarter 2022 earnings per share (EPS) for ResMed in a note to investors on Thursday, August 5. William Blair analyst Mr. Kaczor now predicts the medical equipment supplier will post earnings of $ 1.27 per share for the quarter, up from its previous forecast of $ 1.22. William Blair also released estimates for ResMed earnings in Q2 2022 at $ 1.41 EPS, Q3 2022 earnings at $ 1.30 EPS, Q4 2022 earnings at $ 1.24 EPS, Q1 2023 earnings at 1 , $ 22 EPS, Q2 2023 earnings at $ 1.35 EPS, Q3 2023 earnings at $ 1.38 EPS and Q4 2023 earnings at $ 1.44 per share. ResMed (NYSE: RMD) last reported its results on Thursday, August 5. The medical device supplier announced EPS of $ 1.35 for the quarter, beating Thomson Reuters’ consensus estimate of $ 1.25 of $ 0.10. ResMed recorded a return on equity of 28.85% and a net margin of 14.79%. During the same period of the previous year, the company earned $ 1.33 per share.

Several other brokerages have also recently commented on RMD. Royal Bank of Canada raised its target price on ResMed from $ 223.00 to $ 238.00 and assigned the company an “underperformance” rating in a report released on Tuesday July 27th. Oppenheimer raised its target price on ResMed from $ 240.00 to $ 270.00 and gave the company an “outperformance” rating in a report released on Tuesday, June 15. Robert W. Baird assumed the cover of ResMed in a research note on Monday, June 21. They issued a “neutral” rating and a target price of $ 240.00 on the stock. Macquarie downgraded ResMed from a “neutral” rating to an “outperforming” rating in a Tuesday, June 22 research note. Finally, CLSA downgraded ResMed from an “outperformance” rating to a “sell” rating in a Monday August 2 research note. Three equity research analysts rated the stock with a sell rating, seven gave the company a conservation rating, and four rated the company a buy rating. ResMed currently has an average “Hold” rating and an average price target of $ 239.33.

(A d)

The NASDAQ CEO calls it: “The greatest opportunity we can think of in the next decade.”

RMD shares opened at $ 274.69 on Monday. The company has a 50-day moving average of $ 243.89. ResMed has a one-year minimum of $ 165.72 and a one-year maximum of $ 277.49. The company has a market cap of $ 39.97 billion, a PE ratio of 87.76, a PEG ratio of 3.18 and a beta of 0.30. The company has a leverage ratio of 0.27, a current ratio of 1.67, and a quick ratio of 1.12.

A number of institutional investors have recently changed their positions in the stock. WCM Investment Management LLC increased its stake in ResMed by 1.3% during the second quarter. WCM Investment Management LLC now owns 9,106,110 shares of the medical device supplier valued at $ 2,244,838,000 after purchasing an additional 116,399 shares in the last quarter. Baillie Gifford & Co. increased its stake in ResMed by 4.5% during the second quarter. Baillie Gifford & Co. now owns 3,240,089 shares of the medical device supplier valued at $ 798,746,000 after purchasing an additional 139,261 shares in the last quarter. Geode Capital Management LLC increased its stake in ResMed by 2.2% during the first quarter. Geode Capital Management LLC now owns 2,594,513 shares of the medical device supplier valued at $ 502,128,000 after purchasing an additional 56,193 shares in the last quarter. Janus Henderson Group PLC increased its stake in ResMed by 38.1% in the 1st quarter. Janus Henderson Group PLC now owns 1,726,801 shares of the medical device supplier valued at $ 335,034,000 after purchasing an additional 476,477 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in ResMed by 0.3% in the first quarter. Bank of New York Mellon Corp now owns 1,417,988 shares of the medical device supplier valued at $ 275,117,000 after purchasing 4,164 additional shares during the period. Institutional investors and hedge funds hold 67.15% of the company’s shares.

In related news, CFO Brett Sandercock sold 2,500 shares of the company in a trade on Thursday, June 10. The stock was sold for an average price of $ 212.84, for a total trade of $ 532,100.00. Following the completion of the sale, the Chief Financial Officer now owns 90,002 shares of the company, valued at $ 19,156,025.68. The sale was disclosed in a file with the Securities & Exchange Commission, which is available at this link. Also, COO Robert andrew douglas sold 8,000 shares of the company in a trade on Monday, May 17th. The stock was sold for an average price of $ 195.00, for a total value of $ 1,560,000.00. As a result of the sale, the COO now owns 8,766 shares of the company, valued at approximately $ 1,709,370. Disclosure of this sale can be found here. Insiders have sold 38,274 shares of the company valued at $ 8,855,386 in the past ninety days. 1.33% of the shares are held by insiders.

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 23. Shareholders of record on Thursday, August 19 will receive a dividend of $ 0.42 per share. This represents a dividend of $ 1.68 on an annualized basis and a dividend yield of 0.61%. This is a positive change from ResMed’s previous quarterly dividend of $ 0.39. The ex-dividend date of this dividend is Wednesday August 18. ResMed’s dividend payout ratio is currently 32.77%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes and markets medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders including sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease and other diseases. chronic. The company operates in two segments, sleep and respiratory care, and software as a service.

Read more: Technical analysis of stocks, how can it help

History and earnings estimates for ResMed (NYSE: RMD)

This instant news alert was powered by narrative science technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in ResMed now?

Before you consider ResMed, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the top five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of… and ResMed was not on the list.

While ResMed currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here


Source link

Leave A Reply

Your email address will not be published.